Experience of the use of zoledronic acid (Rezoklastin 5 mg/6.25 ml, OOO «NATIVA») in patients with low bone mineral density in the settings of the center for prevention of osteoporosis of Novosibirsk SRITO
- Authors: Kulyaev E.A1, Grafov A.V1, Falameeva O.V1, Kholodkin V.S1, Sadovoy M.A1,2, Tsygankova O.V2
-
Affiliations:
- FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH
- SBEI HPE Novosibirsk State Medical University of RMH
- Issue: No 19 (2017)
- Pages: 78-81
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/290038
- ID: 290038
Cite item
Open Access
Access granted
Abstract
Full Text
About the authors
E. A Kulyaev
FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH
Email: EKulyaev@niito.ru
Junior Researcher, Traumatologist-Orthopedist at the Center for the Prevention of Osteoporosis
A. V Grafov
FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH
O. V Falameeva
FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH
V. S Kholodkin
FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH
M. A Sadovoy
FSBI SRI of Traumatology and Orthopedics n.a Ya.L. Tsivyan of RMH; SBEI HPE Novosibirsk State Medical University of RMH
O. V Tsygankova
SBEI HPE Novosibirsk State Medical University of RMH
References
- Инструкция по медицинскому применению препарата Резокластин гос. № ЛСР- 003578/10.
- Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Guide S., Wu W., Mangood A., Russell R.G., Ebetino F.H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617-27.
- Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates. J. Pharmacol. Exp. Ther. 2001;296:235-42.
- Rogers M.J., Frith J.C., Luckman S.P. et al. Molecular mechanisms of action of bisphosphonates. Bone. 1999 (Suppl. 5):73-9.
- Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100
- Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991;88:2095-105.
- Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 2003;9(32):2643-58.
- Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995;10:1478-87.
Supplementary files
